Methodology for the published uptake and benefits information

NHS Federated Data Platform uptake

Measure Explanation
Number of sites live with NHS FDP or have signed an MoU to adopt FDP Trusts and ICBs that have either signed a Memorandum of Understanding to join NHS FDP or who have at least one NHS FDP product in live operational use.

Inpatients Care Co-ordination Solution

Measure Explanation
Uptake of Inpatients Care Co-ordination Solution Number of trusts realising benefits from using the product.
Total number of additional patients undergoing procedures
in theatres		 Using Model Hospital System data, the ‘pre’ product deployment average weekly number of patients treated in theatres is calculated.

This is based on 6 months data prior to deployment. This ‘pre’ deployment average weekly number is multiplied by the number of weeks the product has been live post deployment to calculate the ‘pre’ deployment cumulative number of patients treated in theatres. A similar process calculates the cumulative number of patients treated in theatres ‘post’ deployment.

To calculate the additional number of patients treated in theatres, the ‘pre’ cumulative number is subtracted from the ‘post’ cumulative number.
Total number of patients no longer waiting for treatment, requested for removal from the waitlist. The total cumulative number of patient entries requested for removal from the waiting list using the Inpatients CCS product, since its implementation.

Outpatients Care Co-ordination Solution (CCS)

Measure Explanation
Number of trusts using Outpatient Care Co-ordination Solution Number of trusts realising benefits from using the product.
Total number of patients no longer waiting for treatment, requested for removal from the waitlist The total number of patient entries requested for removal from the waiting list using the Outpatients CCS product, since its implementation.

Referral to Treatment (RTT) Period Validation Product

Measure Explanation
Number of trusts and integrated care boards (ICBs) using
Referral to Treatment Validation Product		 Number of trusts realising benefits from using the product.
Total number of RTT
period validations.		 Count of the cumulative total number of unique RTT periods that have been validated using the RTT validation product, since its implementation.
Total number of RTT
period validation closures.		 Count of the cumulative total number of RTT periods that have a validation comment with an outcome of ‘Pathway Closure’ using the RTT validation product, since its implementation.

OPTICA Discharge Planning Product

Measure Explanation
Number of trusts and ICBs using OPTICA Discharge Planning product  Number of trusts realising benefits from using the product.
Percentage change in average number of delay days for 7+ stay cohort patients after rolling out OPTICA. This metric compares the number of delay days for the 7++ stay cohort, for the 12 months before and rolling 12 months after the introduction of OPTICA in trusts with the product, using NHS England sitrep data.
Percentage change in average number of delay days for 14+ stay cohort patients after rolling out OPTICA. This metric compares the number of delay days for the 14+ stay cohort, for the 12 months before and rolling 12 months after the introduction of OPTICA in trusts with the product, using NHS England sitrep data
Percentage change in average number of delay days for long stay (21+ stay cohort) patients after rolling out OPTICA This metric compares the number of delay days for the 21+ stay cohort, for the 12 months before and rolling 12 months after the introduction of OPTICA in trusts with the product, using NHS England sitrep data.

* Long stay patients are those in hospital for 21 days + and a delay day is any day that a patient is still in hospital after they have been declared medically fit to go home.
Total count of OPTICA patients discharged An OPTICA patient is defined as a patient with one or more tasks recorded in the OPTICA tool at the point of discharge.

Cancer 360 Product

Measure  Explanation
Number of Trusts using the Cancer 360 product Number of Trusts realising benefits from using the product
Average improvement against 28-day Faster Diagnosis Standard (patients receiving a cancer diagnosis or cancer ruled out within 28 days of a cancer referral) This metric compares the 28-day Faster Diagnosis Standard, for the 12 months before and the latest (up to) 12 month rolling average after the introduction of Cancer360 in trusts with the product, using NHS England CWT national submissions data.
Average improvement against 31-day Referral to Treatment target (patients starting treatment within 31 days of a treatment decision) This metric compares the 31-day Faster Diagnosis Standard, for the 12 months before and the latest (up to) 12 month rolling average after the introduction of Cancer360 in trusts with the product, using NHS England CWT national submissions data.
Average improvement against 62-day Referral to Treatment start target (patients starting first treatment or receiving a benign diagnosis within 62 days of referral) This metric compares the 62-day Faster Diagnosis Standard, for the 12 months before and the latest (up to) 12 month rolling average after the introduction of Cancer360 in trusts with the product, using NHS England CWT national submissions data.
Total number of patients supported on their cancer journey with Cancer 360 A cumulative total of unique pathways where a user has created an action using the NHS FDP Cancer 360 product – directly impacting the pathway.